Prognosis
Eli Lilly Covid Antibody Trial Paused Due to Safety Concerns
- The shares fall as company supports monitoring board decision
- Lilly therapy similar to antibody treatment given to Trump
This article is for subscribers only.
Eli Lilly & Co. said enrollment of participants in a clinical trial of its antibody treatment for Covid-19 has been paused due to a potential safety concern, pushing down the company’s shares.
An independent data safety monitoring board recommended pausing enrollment in the U.S. government-sponsored trial, a company spokeswoman said in a statement. Lilly didn’t provide information about what caused the panel to recommend the pause.